USPTO serial 79442092
NXTCL
Reviewed by CopyMark Law Group
Status 661
- Filing date
- Status date
- Registration date
- —
- Examiner
- SWAIN, MICHELE LYNN
- Law office
- TMO LAW OFFICE 116
What this means
This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.
Need help with NXTCL?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Meichelle R. MacGregor
Meichelle R. MacGregor Cowan, Liebowitz & Latman, P.C.114 West 47th StreetNew York, NY 10036United StatesGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 001 | Chemicals for use in science; stem cells for research purposes; stem cells for scientific purposes; cell growth media for growing cells for scientific use; biological preparations for use in industry and science; culture media for cultivating stem cells, other than for medical or veterinary use | ACTIVE | — |
| 005 | Live organs and tissues for surgical purposes; pharmaceutical preparations containing stem cells for the treatment and prevention of autoimmune and inflammatory diseases; stem cells for medical purposes; cells for medical use; pharmaceutical preparations for the prevention of autoimmune diseases; pharmaceutical preparations for the treatment of autoimmune diseases; cell growth media for growing cells for medical use | ACTIVE | — |
| 042 | Scientific research and development; medical and pharmaceutical research services; scientific laboratory services; analytical laboratory services for the development and quality control of advanced therapy medicinal products, cell therapies and gene therapies; scientific services, namely, isolation, expansion, characterisation and cultivation of stem cells relating to the isolation and cultivation of human tissues and cells; consultancy in the field of scientific research; advisory services relating to scientific research; providing information about industrial analysis and research services in the field of cell therapy, gene therapy, stem cell biology and cell therapy, autoimmune diseases and cell-based medicinal products, advanced therapy medicinal products; medical research laboratories; provision of information relating to scientific research in the field of cell therapy, gene therapy, stem cell biology and cell therapy, autoimmune diseases and cell-based medicinal products, advanced therapy medicinal products; research and development of new products for others; scientific research for medical purposes; laboratory research services relating to pharmaceuticals; research and development in the pharmaceutical and biotechnology fields; research and development in the field of microorganisms and cells; scientific research in the nature of conducting clinical trials for others; culturing of cells for others for scientific research purposes; stem cell research; quality control for others; providing scientific research information in the field of genetics; providing medical research information in the field of genetics; providing medical and scientific research information in the field of pharmaceuticals and clinical trials; providing information about the results of clinical trials for pharmaceutical products; pharmaceutical research services; development of pharmaceutical preparations and medicines; pharmaceutical products development | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Oct 7, 2026 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Oct 7, 2026 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Oct 7, 2026 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| May 7, 2026 | RFNT | REFUSAL PROCESSED BY IB | — |
| Apr 22, 2026 | RFCS | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | — |
| Apr 22, 2026 | RFRR | REFUSAL PROCESSED BY MPU | — |
| Mar 11, 2026 | RFCR | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | — |
| Mar 10, 2026 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Mar 5, 2026 | DOCK | ASSIGNED TO EXAMINER | — |
| Jan 26, 2026 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| Jan 26, 2026 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Jan 22, 2026 | REPR | SN ASSIGNED FOR SECT 66A APPL FROM IB | — |